Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib + Ruxolitinib in Myelofibrosis
NCT02718300Phase 2Terminated
- Sponsor
- Incyte
- Start
- Feb 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of parsaclisib in myelofibrosis (MF), sponsored by Incyte. Started Feb 2017; status: terminated.
02
Drugs
parsaclisib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02718300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718300.